Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Type 2 diabetes mellitus: a review of current trends.

Olokoba AB, Obateru OA, Olokoba LB.

Oman Med J. 2012 Jul;27(4):269-73. doi: 10.5001/omj.2012.68.

2.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
3.

Diabetes mellitus: new drugs for a new epidemic.

Nicholson G, Hall GM.

Br J Anaesth. 2011 Jul;107(1):65-73. doi: 10.1093/bja/aer120. Review.

PMID:
21610015
4.

Management of type 2 diabetes: new and future developments in treatment.

Tahrani AA, Bailey CJ, Del Prato S, Barnett AH.

Lancet. 2011 Jul 9;378(9786):182-97. doi: 10.1016/S0140-6736(11)60207-9. Review.

PMID:
21705062
5.

Pharmacologic treatment of type 2 diabetes: oral medications.

Tran L, Zielinski A, Roach AH, Jende JA, Householder AM, Cole EE, Atway SA, Amornyard M, Accursi ML, Shieh SW, Thompson EE.

Ann Pharmacother. 2015 May;49(5):540-56. doi: 10.1177/1060028014558289. Review.

PMID:
25667196
6.

Pharmacologic treatment of type 2 diabetes: injectable medications.

Tran L, Zielinski A, Roach AH, Jende JA, Householder AM, Cole EE, Atway SA, Amornyard M, Accursi ML, Shieh SW, Thompson EE.

Ann Pharmacother. 2015 Jun;49(6):700-14. doi: 10.1177/1060028015573010. Review.

PMID:
25802244
7.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

8.

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Abbatecola AM, Maggi S, Paolisso G.

Drugs Aging. 2008;25(11):913-25. doi: 10.2165/0002512-200825110-00002. Review.

PMID:
18947259
9.

Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

Vos RC, van Avendonk MJ, Jansen H, Goudswaard AN, van den Donk M, Gorter K, Kerssen A, Rutten GE.

Cochrane Database Syst Rev. 2016 Sep 18;9:CD006992. [Epub ahead of print] Review.

PMID:
27640062
10.

Complementing insulin therapy to achieve glycemic control.

Barnett AH.

Adv Ther. 2013 Jun;30(6):557-76. Review.

PMID:
23797471
11.

The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.

Munir KM, Davis SN.

Expert Opin Pharmacother. 2015;16(15):2331-41. doi: 10.1517/14656566.2015.1084502. Review.

PMID:
26340427
12.

Pharmacological management of type 2 diabetes mellitus: an update.

El-Kaissi S, Sherbeeni S.

Curr Diabetes Rev. 2011 Nov;7(6):392-405. Review.

PMID:
21846326
13.

Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.

Ovalle F.

Clin Ther. 2011 Apr;33(4):393-407. doi: 10.1016/j.clinthera.2011.04.006. Review.

PMID:
21635987
14.

[Drug treatment of type 2 diabetes].

Tielmans A, Laloi-Michelin M, Coupaye M, Virally M, Meas T, Guillausseau PJ.

Presse Med. 2007 Feb;36(2 Pt 2):269-78. Review. French.

PMID:
17258675
15.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Review.

PMID:
23263796
16.

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.

Hermansen K, Mortensen LS.

Drug Saf. 2007;30(12):1127-42. Review.

PMID:
18035865
17.

Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.

Lau DC, Teoh H.

Can J Diabetes. 2015 Dec;39 Suppl 5:S148-54. doi: 10.1016/j.jcjd.2015.09.090. Review.

PMID:
26654858
18.
19.

Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Roussel R, Lorraine J, Rodriguez A, Salaun-Martin C.

Adv Ther. 2015 Nov;32(11):1029-64. doi: 10.1007/s12325-015-0261-x. Review.

PMID:
26581749
20.

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.

Wong MC, Wang HH, Kwan MW, Zhang DD, Liu KQ, Chan SW, Fan CK, Fong BC, Li ST, Griffiths SM.

PLoS One. 2014 Mar 10;9(3):e90963. doi: 10.1371/journal.pone.0090963. Review.

Items per page

Supplemental Content

Support Center